A novel deep intronic EIF2AK3 variant disrupts splicing and causes Wolcott–Rallison syndrome
Authors:
Open Access
- 3 September 2026
- journal article
- Published by Wiley in Diabetic Medicine
Abstract
Aim: Deep intronic variants can disrupt splicing and cause monogenic disease but are missed by routine genetic testing. This study assessed the contribution of deep intronic variants to Wolcott–Rallison syndrome (WRS), a recessive disorder characterized by early‐onset diabetes and progressive multisystem disease caused by loss‐of‐function EIF2AK3 variants. Methods: We investigated a cohort of 116 individuals referred to the Exeter Genomics Laboratory for genetic testing who had diabetes diagnosed at ≤2 years and at least one additional feature consistent with WRS: hepatic dysfunction, skeletal abnormalities or developmental delay. No genetic cause had been identified after testing all known early‐onset diabetes genes. We screened genome‐sequencing data for rare homozygous intronic EIF2AK3 variants. Candidate variants predicted to affect splicing by SpliceAI were assessed using a minigene exon‐trapping assay. Results: We identified two rare homozygous intronic EIF2AK3 variants in two siblings. Only one variant, c.1651‐180G>T, was predicted to disrupt splicing in silico. The two children, born to consanguineous parents, were diagnosed with early‐onset diabetes (diagnosed at 1 year and 21 weeks), hepatic dysfunction, skeletal abnormalities, developmental delay, thyroid dysfunction, hip dysplasia and gait abnormalities. The minigene assay showed that c.1651‐180G>T creates a cryptic donor splice site within intron 9, resulting in inclusion of a 79‐nucleotide pseudoexon, causing a frameshift and premature stop codon. Using this evidence, the variant was reclassified as likely pathogenic according to ACMG/ACGS guidelines. Conclusions: We report the first deep intronic EIF2AK3 variant causing WRS, highlighting the need to consider systematic intronic analysis in unresolved cases.Keywords
Funding Information
- National Institute for Health and Care Research
- British Heart Foundation
- Academy of Medical Sciences
- Diabetes UK (21/0006335)
- European Foundation for the Study of Diabetes
- Wellcome Trust (224600/Z/21/Z)
- Wellcome Trust (223187/Z/21/Z)
- Academy of Medical Sciences (SBF009\1135)
This publication has 28 references indexed in Scilit:
- Using the ACMG/AMP framework to capture evidence related to predicted and observed impact on splicing: Recommendations from the ClinGen SVI Splicing SubgroupThe American Journal of Human Genetics, 2023
- High-throughput splicing assays identify missense and silent splice-disruptive POU1F1 variants underlying pituitary hormone deficiencyThe American Journal of Human Genetics, 2021
- Benchmarking deep learning splice prediction tools using functional splice assaysHuman Mutation, 2021
- Predicting Splicing from Primary Sequence with Deep LearningCell, 2019
- Splicing mutations in human genetic disorders: examples, detection, and confirmationJournal of Applied Genetics, 2018
- Deep intronic mutations and human diseaseHuman Genetics, 2017
- The effect of early, comprehensive genomic testing on clinical care in neonatal diabetes: an international cohort studyThe Lancet, 2015
- From FastQ Data to High‐Confidence Variant Calls: The Genome Analysis Toolkit Best Practices PipelineCurrent Protocols in Bioinformatics, 2013
- Use of Splicing Reporter Minigene Assay to Evaluate the Effect on Splicing of Unclassified Genetic Variants2010
- EIF2AK3, encoding translation initiation factor 2-α kinase 3, is mutated in patients with Wolcott-Rallison syndromeNature Genetics, 2000